Clinical Trials Browser

Hematologic Diseases × pembrolizumab × Clear all

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Phase 2 Withdrawn

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms